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ABSTRACT
Poor intrauterine and childhood growth has been linked with the risk of osteoporosis in later life, a relationship that may in part be
mediated through altered epigenetic regulation of genes. We previously identiﬁed a region within the promoter of the long non-
coding RNA ANRIL encoded by the CDKN2A locus, at which differential DNA methylation at birth showed correlations with offspring
adiposity. Given the common lineage of adipocytes and osteoblasts, we investigated the relationship between perinatal CDKN2A
methylation and bone mass at ages 4 and 6 years. Using sodium bisulﬁte pyrosequencing, we measured the methylation status of
the 9 CpGs within this region in umbilical cord samples from discovery (n¼ 332) and replication (n¼ 337) cohorts of children from
the SouthamptonWomen’s Survey, whose bonemass was assessed by dual-energy X-ray absorptiomietry (DXA; Hologic Discovery).
Inverse associations were found between perinatal CDKN2Amethylation and whole-body minus head bone area (BA), bone mineral
content (BMC), and areal bone mineral density (BMD). This was conﬁrmed in replication and combined data sets (all p< 0.01), with
each 10% increase in methylation being associated with a decrease in BMC of 4 to 9 g at age 4 years (p 0.001). Relationships were
similar with 6-year bone mass. Functional investigation of the differentially methylated region in the SaOS-2 osteosarcoma cell line
showed that transcription factors bound to the identiﬁed CpGs in a methylation-speciﬁc manner and that CpG mutagenesis
modulated ANRIL expression. In conclusion, perinatal methylation at CDKN2A is associated with childhood bone development and
has signiﬁcance for cell function. © 2017 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
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Introduction
Although there is evidence of a substantial heritable componentto bone mineral density (BMD),(1,2) there is increasing evidence
that interactions between environment and genotype, leading to
altered gene expression, may contribute to the overall variance in
BMD.(3) Previous population studies have shown that poor
intrauterine and childhood growth are predictors of osteoporosis
in later life and of adult hip fracture.(4,5) Maternal factors, such as diet
before and during pregnancy, lifestyle (eg, cigarette smoking and
physical activity), body composition, vitamin D status during
pregnancy, and also paternal factors, such as skeletal size, have all
been associated with offspring bone development.(6–10) Evidence
that such associations between environmental factors at critical
periods of early development and later health and diseasemight be
mediated by epigenetic mechanisms have come from the natural
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world and also from experimental animal studies in which altered
gestational diet in rat models leads to modiﬁcation of DNA
methylation, gene expression, and phenotype in the off-
spring.(3,11–13) Previously, a candidate gene approach from our
group has demonstrated that methylation at the Retinoid X
Receptor–alpha (RXRA) promoter in umbilical cordDNA is associated
with offspring bone mass in childhood,(14) complementing our
documentedassociationsbetweenoffspring fatmass,perinatalRXRA
methylation, and methylation at a further gene, CDKN2A.(15–17)
There is evidence that DNA methylation at various genes,
including cyclin-dependent kinases such as CDKN2A, plays a role
in skeletal development, homeostasis, andbone cell activity. Thus
methylation has been implicated in mechanisms of osteoblastic
differentiation(18–20) andosteoclastogenesis,(21) togetherwith the
transition from osteoblast to osteocyte.(22–25) These experimental
ﬁndings are complemented by data from genome-wide meth-
ylation proﬁling studies in older patients, demonstrating
differential methylation at genes such as the cyclin-dependent
kinase inhibitor CKDN1C and cyclin-dependent kinase CDK20 is
associated with BMD.(26,27) These ﬁndings, therefore, indicate the
importance of epigenetic processes in bone metabolism,
particularly with regard to loci implicated in cellular differentia-
tion, cell cycle regulation, and bone cell function.
The CDKN2A locus encodes two cell cycle inhibitors: p14ARF
and P16INK4a, which play roles in cellular senescence and aging.
The CDKN2A locus also encodes the long non-coding RNA ANRIL
(antisense non-coding RNA in the INK4 locus), a 3834 bp
transcript that can negatively regulate p16INK4a. Single-nucleo-
tide polymorphisms (SNPs) within the CDKN2A locus, particularly
those located within ANRIL, have been associated with
cardiovascular disease, diabetes, and frailty,(28) and DNA
methylation at this locus has recently been demonstrated to
vary with age.(29) Given our previous demonstration of links
between perinatal CDKN2A methylation and offspring fat
mass,(16) together with the common mesenchymal origin and
well-established functional relationships between fat and bone,
mediated via both mechanical and endocrine pathways,(30) we
carried out a targeted approach to examine DNAmethylation at
CpG sites within the CDKN2A gene. We examined DNA
methylation across a 300 bp region within the promoter region
of ANRIL that contained 9 CpG dinucleotides (a cytosine
immediately preceding a guanine base in the 5’ to 3’ direction).
We hypothesised that DNA methylation at birth would be
associated with offspring bone mass in childhood. To test this,
we examined DNA methylation levels in relation to BMD in a
discovery cohort, then replicated our ﬁndings in a second
separate cohort. We also carried out functional analysis of the
region to determine its importance for local gene expression
and transcription factor binding.
Materials and Methods
Southampton Women’s Survey (SWS)
A detailed description of the SWS, a prospective mother-
offspring birth-cohort study in Southampton, UK, has been
published previously.(31) Brieﬂy, non-pregnant women aged 20
to 34 years were recruited into the study (n¼ 12,583) between
April 1998 and October 2002. A total of 3158 women who
subsequently became pregnant and delivered a liveborn
singleton infant between December 1998 and December 2007
were phenotyped in detail during pregnancy, and their offspring
have been followed up during childhood.
Offspring bone assessment
A consecutive subset of children was invited to visit the
Osteoporosis Centre at Southampton General Hospital for
assessment of bone mass and body composition at age 4 years.
At this visit, written informed consent for a dual-energy X-ray
absorptiometry (DXA) scan was obtained from the mother or
father/guardian. The child’s height (Leicester height measurer,
Seca Ltd, Birmingham, UK) and weight (in underpants only,
using calibrated digital scales, Seca Ltd) were measured. A
whole-body DXA scan was obtained, using a Hologic Discovery
instrument (Hologic Inc., Bedford, MA, USA) in pediatric scan
mode. Scans with unacceptable movement artefact were
excluded. The manufacturer’s coefﬁcient of variation (CV) for
the instrument was 0.75% for whole-body bonemineral density,
and the experimental CV when a spine phantomwas repeatedly
scanned in the same position 16 times was 0.68%. A similar bone
assessment was undertaken at age 6 years. The SWS was
conducted according to the guidelines laid down in the
Declaration of Helsinki, and the Southampton and South West
Hampshire Research Ethics Committee approved all procedures.
Umbilical cord DNA extraction
A 5- to 10-cm segment was cut from the mid portion of each
cord immediately after delivery, ﬂushed with saline to remove
fetal blood, ﬂash-frozen in liquid nitrogen, and stored at
80°C until required for DNA isolation. Genomic DNA was
isolated from frozen archived umbilical cord tissue by classical
proteinase K digestion and phenol:chloroform extraction.
Quantitative DNA methylation analysis and
pyrosequencing: study and replication cohorts
The region of interest within the CDKN2A gene locus is located
within the promoter region of the non-coding RNA ANRIL,
transcribed from this gene locus, and contains 9 CpG
dinucleotides (chr9: 21993583-21993721) (Fig. 1). We used
sodium bisulﬁte targeted pyrosequencing (Pyromark MD,
Qiagen, Valencia, CA, USA; https://www.qiagen.com/ﬁ/
resources/technologies/pyrosequencing-resource-center/
technology-overview/)(32) to carry out in-depth analysis of the
methylation status of these 9 CpGs within the previously
identiﬁed differentially methylated region of CDKN2A in
umbilical cords. The analysis followed a discovery/replication
design, with methylation status measured in an initial
consecutive series of umbilical cords from SWS deliveries
(Discovery cohort), on whom childhood DXA assessment had
been undertaken. Subsequently, when DXA measures had
become available on a further separate subset of SWS children,
methylation at these CpG sites was measured in a second,
consecutive and independent series of SWS deliveries
(Replication cohort). Inter- and intraplate controls were added
to each plate as a control for inter- and intraplate variability,
and 0% and 100% methylation controls were run to ensure
that the full range of methylation could be detected. The
summary statistics for methylation (minimum, maximum,
quartile 1, median, quartile 3), plus mean and SD, together
with the genomic coordinates for the CDKN2A CpG sites are
shown in Supplemental Table S1. Details of the studies of
functional validation in osteosarcoma SaOS-2 cells are
presented in the Supplemental Material and summarized in
the relevant paragraphs of the Results section.
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Statistical analysis
Statistical analysiswasundertakenusingStata (StataCorp,College
Station, TX, USA; versions 14.0/14.1/14.2). The data were checked
to ensure that the assumptions of linear regression were met.
Regression models were built using the offspring bone indices
measured by DXA (at either 4 or 6 years) as the outcome and CpG
methylation as thepredictor. Results are presented as thenumber
of observations in each regression and regression coefﬁcients (b)
with their associated p values and 95% conﬁdence intervals. b
coefﬁcients represent the change in the bone outcome per 10%
change in methylation at each CpG site. This analysis was initially
performed on the SWS Discovery cohort, repeated in the SWS
Replication cohort, and then analysis was performed on the two
cohorts combined, described as the SWS Combined cohort, in
order to maximize statistical power for further multivariate
analyses. All models were adjusted for the child’s sex and age at
DXA scan, except for at 4 years where an adjustment for age was
not necessary because of the narrow age range at which the DXA
scans were performed. Where analysis was performed on the
Combined cohort, an indicator representing cohort was included
as a covariate in the model to account for batch effect. In
multivariate models, we accounted for potential confounding
factors previously found to be associated with offspring bone
development (mother’s pre-pregnancy height, maternal parity,
late pregnancywalking speed, late pregnancymaternal smoking,
and late pregnancy triceps skinfold thickness). In further analyses,
we explored the effect of the covariates potentially on the causal
pathway, including offspring birthweight, and childhood height,
weight, lean mass, and fat mass.
Recognizing that therewas likely tobeco-linearitybetween the
individual exposures andbetween theDXA indices, and given the
relatively small number of tests in our analysis compared with
larger-scale genome-wide association studies, for whichmethods
such as Bonferroni or the Benjamini-Hochberg/False Discovery
Rate corrections for multiple testingwould be appropriate,(33) we
undertook a data reduction approach by investigating clustering
of theCpGmethylation. Importantly, there is evidence thatwhere
clusters of differential CpGs can be identiﬁed, they aremore likely
to be functional than are individual CpG changes.(34) By
investigating the correlation between methylation at each of
the individual CpG sites and calculating the median absolute
deviation (MAD) from the median for each site, we grouped the
CpG sites into 4 clusters (CpG1-2, 3, 4-7, 8-9), with each cluster
represented by the site with the highest MAD score (ie, the site
with the greatest variability within the cluster), that is, CpG sites 2,
3, 7, and 9, respectively (summarized in Supplemental Fig. S2). For
completeness, we also used the Simes modiﬁcation of the
Benjamini-Hochberg method to undertake a p value correction
on the analyses in the Combined data set, using the Stata
“qqvalue” command, which is similar to the “p.adjust” command
in R.(34) These are presented as q values in Supplemental Table S7.
Results
Characteristics of the subjects
There were 332 mother and child pairs with methylation
measurements at the 9 CpG sites within the CDKN2A locus and
DXA data at either 4 years or 6 years of age in the SWS Discovery
cohort, 374 in the SWS Replication cohort, and 706 in the SWS
Combined cohort, in which the Study and Replication cohorts
were combined. Tables 1 and 2 summarize the characteristics of
the mothers and children in the Discovery, Replication, and
Combined cohorts. Compared with mothers in the SWS as a
whole, mothers in the ﬁnal Combined cohort were slightly taller
(p¼ 0.004), less likely to smoke during pregnancy (p¼ 0.049),
and had higher educational qualiﬁcations (p< 0.001) and higher
socioeconomic status (p< 0.001).
Fig. 1. Location of CpG dinucleotides in relation to the known genes in the CDKN2A region. Region of interest: 21993583-21993721 (human genome
hg19/GRCh37 build). The top ﬁgure shows the UCSC-genome annotation for this region; the lower ﬁgure comprises a clariﬁed schematic diagram
focusing on local gene layout with relevant distances marked in base pairs and the CpG dinucleotides of interest marked on an annotated primary
sequence.
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CDKN2A methylation is associated with offspring bone
size, mineralization, and areal density
Percentage methylation at the 9 CpG sites varied greatly, from
17.1% to 99.6% (Supplemental Table S1). Tables 3 and 4 show
that there were inverse associations between CpG methylation
at sites 3, 7, and 9 (with CpGs 7 and 9 representing the clusters
CpG4-7 and CpG8-9) and offspring whole-body minus head
bone indices at 4 years. Because the relationships were similar
in both cohorts, we used the Combined Cohort for all
remaining analysis (Table 5, Fig. 2). Thus, in the combined
cohort, both unadjusted and after adjustment for batch effect,
mother’s late pregnancy (LP) walking speed, LP smoking,
prepregnancy height, LP triceps skinfold thickness, and parity,
there were strongly statistically signiﬁcant inverse associations
between CpG methylation at CpG sites 3, 7, and 9 (but not
CpG2) with the bone indices at 4 years (Table 6). Similar
inverse associations were observed at 6 years (Supplemental
Table S3). At other CpG sites, inverse but non-statistically
signiﬁcant associations were observed. The effect sizes were
similar across different CpG sites and the two different ages;
for example, for every 10% increase in methylation at CpG9,
there was a 9.1 g decrease in whole-body minus head BMC at
age 4 years and a 10.2 g decrease at age 6 years. In further
analyses aimed at identifying potential mediators of the
methylation-bone relationship, the CpG-bone associations
remained robust after inclusion of child’s whole-body lean
mass or fat mass or child’s birthweight in the multivariate
models (Supplemental Table S4). CpG-bone associations for
total BMC and total BMD also persisted after adjustment for
the child’s height at DXA (Supplemental Table S5), though
associations between CpG methylation and total BA were
attenuated. Adjustment for body weight markedly attenuated
the associations to below statistical signiﬁcance.
Functional analysis of the differentially methylated
region of CDKN2A in osteosarcoma cells
Because the 9 CpG sites are located within the promoter region
of the long non-coding RNA ANRIL, we next investigated
whether the CpG sites might be important for the expression of
ANRIL. The promoter region of ANRIL (–1281 bp to þ20 bp
relative to TSS) was fused upstream of the luciferase reporter
gene in pGL3Basic. The 9 CpG sites were then individually
Table 1. Characteristics of the SWSMothers in the Study Cohort (SWS 1st 400), Replication Cohort (SWS 2nd 400), and Combined Cohort
(SWS 800)
Characteristic
% or median (5th, 95th
percentile) for SWS Study cohort
mean (SD) n¼ 332
% or median (5th, 95th percentile)
for SWS Replication cohort mean
(SD) n¼ 374
% or median (5th, 95th percentile)
for combined SWS cohort mean
(SD) n¼ 706
Woman’s age at birth
of child (years)
30.44 (3.5) 31.23 (3.6) 30.86 (3.6)
Body mass index 24.29 (19.8, 34.6) 24.10 (19.6, 34.4) 24.19 (19.7, 34.6)
Maternal height (cm) 163.72 (6.7) 163.91 (6.2) 163.82 (6.4)
Maternal weight (kg) 66.0 (52.2, 93.8) 64.8 (51.9, 96.3) 65.7 (51.9, 94.3)
Late pregnancy mid
upper arm
circumference (cm)
30.04 (3.5) 30.37 (3.7) 30.22 (3.6)
Smoking (during
pregnancy)
13.64% 14.21% 13.94%
Educational qualifications
None 0.90 % 2.43% 1.71%
CSE 8.73% 8.89% 8.82%
O levels 26.81% 27.76% 27.31%
A levels 27.11% 35.04% 31.29%
HND 9.04% 6.47% 7.68%
Degree 27.41% 19.41% 23.19%
Social class
Professional 6.75% 4.62% 5.62%
Management and
technical
42.64% 39.13% 40.78%
Skilled non-manual 32.21% 37.50% 35.01%
Skilled manual 6.75% 7.07% 6.92%
Partly skilled 10.74% 10.33% 10.52%
Unskilled 0.92% 1.36% 1.15%
Late pregnancy walking speed
Very slow 15.26% 16.76% 16.06%
Stroll at an easy
pace
53.58% 52.43% 52.97%
Normal speed 26.48% 23.78% 25.04%
Fairly brisk 4.36% 6.76% 5.64%
Fast 0.31% 0.27% 0.29%
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Table 2. Characteristics of the SWS Children in the Discovery, Replication, and Combined Cohorts
% or median (5th, 95th percentile) mean (SD)
Characteristic
Discovery cohort
n¼ 332
Replication cohort
n¼ 374
Combined cohort
n¼ 706
Female 47.89% 51.34% 49.72%
Birth order
1st 47.59% 51.07% 49.43%
2nd 39.46% 36.10% 37.68%
3rd or lower 12.95% 12.83% 12.89%
Birth weight (kg) 3.46 (0.5) 3.53 (0.5) 3.50 (0.5)
Gestational age (weeks) 40.00 (36.6, 41.9) 40.14 (37.1, 41.9) 40.12 (37.0, 41.9)
Placental weight (g) 467.95 (99.3) 479.09 (104.2) 473.94 (102.0)
4-Year child DXA bone indicesa
4-Year age at DXA scan 4.1 (4.0, 4.2) 4.1 (4.0, 4.2) 4.1 (4.0, 4.2)
Total BMC (g) 374.6 (45.0) 371.8 (45.3) 373.2 (45.1)
Total BMD (g/cm2) 0.37 (0.05) 0.37 (0.05) 0.37 (0.05)
Total BA (cm2) 0.49 (0.04) 0.49 (0.04) 0.49 (0.04)
4-Year total fat massa (kg) 4.1 (2.9, 6.7) 4.1 (3.0, 6.7) 4.1 (2.9, 6.7)
4-Year total lean massa (kg) 9.86 (1.3) 9.73 (1.3) 9.79 (1.3)
6-Year child bone DXA indicesb
6-Year age at DXA scan 6.6 (6.3, 7.0) 7.0 (6.5, 7.5) 6.8 (6.3, 7.4)
Total BA (cm2) 908.06 (64.2) 913.18 (62.4) 910.65 (63.3)
Total BMC (g) 547.0 (74.1) 551.6 (77.1) 549.3 (75.6)
Total BMD (g/cm2) 0.60 (0.05) 0.60 (0.05) 0.60 (0.05)
aWhole body minus head site, adjusted for sex.
bWhole body minus head site, adjusted for sex and age.
Table 3. CDKN2A CpG Methylation and Bone Mineral Outcomes at Age 4 Years in the SWS Discovery Cohort (Relationship Between
Methylation at the 9 CpG Sites Within the CDKN2A Region of Interest and Total Bone Area, Bone Mineral Content, and Bone Mineral
Density in the 4-Year-Old Children [Whole Body Minus Head])
Discovery Total BA (cm2) Total BMC (g) Total BMD (g/cm2)
CpG
cluster n b
p
Value 95% CI b
p
Value 95% CI b
p
Value 95% CI
1–2 254 3.07 0.324 (–9.18, 3.05) 3.06 0.297 (8.84, 2.71) 0.0018 0.442 (0.0062, 0.0027)
3 229 3.32 0.428 (–11.57, 4.92) 4.64 0.243 (12.46, 3.17) 0.0037 0.236 (0.0097, 0.0024)
4–7 288 6.94 0.037 (–13.44, –0.44) 6.23 0.05 (12.44, –0.01) 0.0033 0.195 (0.0083, 0.0017)
8–9 262 10.85 0.005 (–18.47, –3.23) 10.27 0.005 (17.47, –3.07) 0.006 0.045 (0.0118, 0.0001)
Associations adjusted for sex.b coefﬁcients and 95%CIs have beenmultiplied by 10 and therefore represent the change associatedwith a 10% increase
in methylation. p values <0.05 are in bold.
Table 4. CDKN2A CpG Methylation and Bone Outcomes at Age 4 Years in the SWS Replication Cohort (Relationship Between
Methylation at the 9 CpG Sites Within the CDKN2A Region of Interest and Total Bone Area, Bone Mineral Content, and Bone Mineral
Density in the 4-Year-Old Children [Whole Body Minus Head])
Replication Total BA (cm2) Total BMC (g) Total BMD (g/cm2)
CpG
cluster n b
p
Value 95% CI b
p
Value 95% CI b
p
Value 95% CI
1–2 245 2.58 0.399 (8.61, 3.44) 4.94 0.09 (10.66, 0.77) 0.0046 0.051 (0.0092, 0.000002)
3 193 9.8 0.016 (17.74, 1.86) 10.22 0.008 (17.76, 2.69) 0.007 0.027 (0.0131, 0.0008)
4–7 267 6.93 0.025 (12.96, 0.89) 9.9 0.001 (15.67, 4.14) 0.0081 0.001 (0.0128, 0.0035)
8–9 216 6.39 0.056 (12.95, 0.17) 8.79 0.008 (15.24, 2.35) 0.007 0.009 (0.0122, 0.0018)
Associations adjusted for sex.b coefﬁcients and 95%CIs have beenmultiplied by 10 and therefore represent the change associatedwith a 10% increase
in methylation. p values <0.05 are in bold.
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mutated (CpG>TpG) and each construct transfected into the
human osteosarcoma cell line SaOS2. Mutation of CpG2-8 led to
a decrease in ANRIL promoter activity (p 0.05), whereas
mutation of CpG1 and CpG9 had no effect on ANRIL promoter
activity (Fig. 3A). To determine whether methylation of the CpG
sites associated with later bone outcomes might affect
transcription factor binding to this region, electrophoretic
mobility shift assays (EMSA) were undertaken (full details in the
Supplemental information). Incubation of nuclear extracts from
SaOS-2 cells with oligonucleotides covering CpG1, CpG2-3,
CpG4-7, and CpG8-9 showed strong speciﬁc binding of protein
complexes to the oligonucleotides containing CpG1 and CpG8-
9, with weaker binding also observed to CpG2-3 and CpG4-7
(Fig. 3B, C).
To test whether DNA methylation affected protein binding,
the CpG8-9 oligonucleotide was incubated with nuclear extracts
Table 5. CDKN2A CpG Methylation and Bone Mineral Outcomes at Age 4 Years in the SWS Combined Cohort (Relationship Between
Methylation at the 9 CpG Sites Within the CDKN2A Region of Interest and Total Bone Area, Bone Mineral Content, and Bone Mineral
Density in the 4-Year-Old Children [Whole Body Minus Head])
Combined Total BA (cm2) Total BMC (g) Total BMD (g/cm2)
CpG
cluster n b
p
Value 95% CI b
p
Value 95% CI b
p
Value 95% CI
1–2 499 2.83 0.1945 (7.11, 1.45) 3.99 0.0538 (8.04, 0.07) 0.0031 0.0543 (0.0064, 0.0001)
3 422 6.52 0.0255 (12.25, 0.80) 7.4 0.0076 (12.83, 1.98) 0.0053 0.0162 (0.0096, 0.0010)
4–7 555 6.93 0.0021 (11.34, 2.52) 8.18 0.0002 (–12.40, 3.96) 0.0059 0.0008 (0.0093, 0.0025)
8–9 478 8.28 0.0011 (13.23, 3.32) 9.42 0.0001 (14.18, 4.65) 0.0066 0.0009 (0.0104, 0.0027)
Associations adjusted for sex and batch. b coefﬁcients and 95% CIs have been multiplied by 10 and therefore represent the change associated with a
10% increase in methylation. p values < 0.05 are in bold.
Fig. 2. CDKN2A CpG methylation in relation to bone mineral outcomes. Percentage methylation at CDKN2A CpG 6 (left) and CpG 9 (right) expressed in
quarters of the distribution in umbilical cord tissue, and offspring total bone area (whole body minus head, cm2), bone mineral content (g), and areal
bone mineral density (g/cm2) at age 4 years.
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Table 6. CDKN2A CpG Methylation and Bone Mineral Outcomes at Age 4 Years Accounting for Maternal Factors in the Combined SWS
Cohort (Relationships Between Methylation at the Clustered CpG Sites Within the CDKN2A Region of Interest and Whole-Body Minus
Head Bone Area, Bone Mineral Content, and Bone Mineral Density in the 4-Year-Old Children)
Combined Total BA (cm2) Total BMC (g) Total BMD (g/cm2)
CpG
cluster n b
p
Value 95% CI b
p
Value 95% CI b
p
Value 95% CI
1–2 484 3 0.1628 (7.21, 1.22) 4.11 0.0407 (8.05, 0.17) 0.0032 0.0429 (0.0064, 0.0001)
3 408 5.93 0.0431 (11.68, 0.18) 7.01 0.0099 (12.33, 1.69) 0.0052 0.0154 (0.0094, 0.0010)
4–7 538 5.85 0.0084 (10.20, 1.51) 7.17 0.0007 (11.30, 3.04) 0.0053 0.0021 (0.0086, 0.0019)
8–9 461 8.26 0.0009 (13.11, 3.41) 9.11 0.0002 (13.79, 4.43) 0.0062 0.0016 (0.0100, 0.0024)
Adjusted for batch, child’s sex, mother’s late pregnancy (LP) walking speed, LP smoking, prepregnancy height, LP triceps skinfold thickness, and parity.
b coefﬁcients and 95% CIs have beenmultiplied by 10 and therefore represent the change associated with a 10% increase inmethylation. p values<0.05
are in bold.
Fig. 3. CpG sites within the DMR are important for the transcriptional regulation of the CDKN2A cluster. (A) Role of CpGs in expression SaOS-2:
cells were transiently transfected with ANRIL promoter constructs in a pGL3-basic reporter background. CMV-renilla was co-transfected for
normalization. (B) Electrophoretic mobility shift assays using nuclear extract from osteosarcoma cell line SaOS-2 to examine nuclear protein
binding to different regions within the DMR. A lane without protein extract was used as negative control, and non-radiolabeled probe at
500 was used as a speciﬁc competitor to examine if binding is speciﬁc to that region of the DMR. (C) EMSAs with unmethylated- and
methylated-speciﬁc competitor were used in increasing concentrations of 100-, 250-, and 500-fold to determine if methylation has an effect
on protein binding to this region. (D) Transient transfection of SaOS-2 cells with 10 nM siRNA against exon 1 of ANRIL successfully knocked
down exon 1 expression in these cells. (E) SaOS-2 cells were treated for 72 hours with “scrambled” siRNA (negative control) and siRNA against
exon 1 of ANRIL. Cells were trypsinized and number of live cells counted for each siRNA treatment. (F) DNA from SaOS-2 cells treated with
“scrambled” and ANRIL exon 1 siRNAs was stained with propidium iodide and FACS analysis used to determine percentage of cells
undergoing apoptosis. Figures represent pooled results from three independent experiments (p< 0.05, p< 0.01, p< 0.001,
p< 0.0001).
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from SaOS-2 cells with a 50-, 100-, and 500-fold excess of
unmethylated- or methylated-speciﬁc competitor, containing a
methylated cytosine at CpGs 8 and 9.(35) Although binding to the
probe was markedly reduced in the presence of a 100-fold
excess of the unmethylated-speciﬁc competitor, there was little
reduction in binding upon the addition of a 100-fold excess of
cold competitor containing the methylated CpGs. When a
methylated probe was used, the unmethylated competitor
again competed out binding much more effectively than the
methylated competitor. Comparison of binding to both the
unmethylated and methylated probes also showed stronger
binding to the unmethylated probe (Supplemental Fig. S2).
To identify which transcription factors bind to this region of
CDKN2A, DNA consensus sequences for 80 common transcrip-
tion factors(35) were used to examine binding within the CpG8-9
region. Transcription factor consensus sequences for interferon-
gamma activated site (GAS) and SMAD3/4 competed-out
binding of radiolabeled probe to the CpG8-9 region in
osteosarcoma cell line extract (Supplemental Fig. S2B). Consis-
tent with these ﬁndings, in silico analysis of ENCODE
ChromHMM data(36) revealed that this region is enriched for
both promoter and enhancer activity across multiple cell types,
as well as overlapping DNase I hypersensitive sites, suggesting
that the CpG sites examined in this article lie within a key
regulatory region of CDKN2A (Fig. 1, Supplemental Fig. S2C).
Having determined that the CpGs sites associated with later
bone outcomes may have functional relevance for ANRIL
promoter activity in osteosarcoma cells, we next investigated
the effect of perturbing ANRIL expression in SaOS-2 cells. SaOS-2
cells were transfected with siRNA directed against ANRIL(28) and
the effect on cell growth and apoptosis assessed. Primer
sequences are summarized in Supplemental Table S2. Transfec-
tion of the ANRIL siRNA caused a ﬁvefold decrease in ANRIL
expression (Fig. 3D) and decreased the number of live cells by
0.3-fold (p 0.001) (Fig. 3E), while increasing the number of cells
undergoing apoptosis (FACS) (p 0.001) (Fig. 3F).
Discussion
We found that lower perinatal methylation of speciﬁc CpG
dinucleotides within the CDKN2A gene locus is associated with
higher total whole-body minus head BA, BMC, and areal BMD at
4 and 6 years of age. Furthermore, we demonstrated that these
CpG sitesmay play a role inmodulating the level of expression of
the long non-coding RNA ANRIL, which regulates cell survival,
suggesting that these relationships have functional relevance.
To our knowledge, this is the ﬁrst time that associations
between CDKN2A methylation and childhood bone develop-
ment and the related consequences for cell survival and gene
expression have been demonstrated. We have previously
published data relating methylation at the Retinoid X Receptor-
alpha (RXRA) to childhood bone mineral content corrected for
body size(14) and associations at this and other sites in relation to
offspring adiposity.(15) The CDKN2A (INK4A-ARF) gene locus
encodes two potent inhibitors of cell growth: p14ARF (alternative
reading frame relative to p16) and p16INK4a (inhibitor of cyclin-
dependent kinase 4). Recently, both p16INK4a and p14ARF have
been shown to play a role in driving cellular senescence and
aging.(37,38) Consistent with a role for the CDKN2A locus in aging,
GWAS studies have shown that SNPs in a region spanning 160 kb
around the CDKN2A locus, with the majority located within
ANRIL, were associated with increased susceptibility to frailty,
coronary artery disease, myocardial infarction, type 2 diabetes,
and late-onset Alzheimer disease.(28,39–45) Although the majority
of these SNPs are located toward the 3’ end of the ANRIL coding
region, more than 100 Kb from the differentially methylated
region (DMR) identiﬁed in this study, these SNP associations and
recent evidence linkingmethylation at CDKN2Awith aging(29) do
highlight the importance of the CDKN2A locus in general and
ANRIL in particular in altered susceptibility to aging-related
diseases.
There is little evidence in the literature for the speciﬁc
involvement of the CDKN2A locus in bonemetabolism, although
p16INK4a expression has been linked to altered osteoblast
morphology and senescence in animal models,(46,47) and one
study identiﬁed transitional hypomethylation of CDKN2A in
human bonemarrow stromal cells in their differentiation toward
an osteoblastic lineage.(18) However, the importance of cyclin-
dependent kinases and their inhibitors has been demonstrated
by studies of the osteogenic differentiation of adipose-derived
mesenchymal stem cells, in which the promoters of RUNX2,
osteocalcin, and osterix genes are actively demethylated in a
process dependent upon growth arrest and DNA-damage-
inducible protein, GADD45, which is known to interact with both
CDK1 and CDKN1A.(19,20) Genome-wide methylation proﬁling
studies in older patients comparing individuals with low versus
normal BMD have also suggested early life inﬂuences on bone
quality in older age.(27) In a genome-wide association study,
genes encoding cyclin-dependent kinase inhibitor CKDN1C and
cyclin-dependent kinase CDK20 have been found to be
differentially methylated in ex vivo bone samples from patients
who have experienced a low-trauma hip fracture comparedwith
those from patients undergoing elective arthroplasty for
osteoarthritis.(26) Furthermore, DMRs enriched in genes associ-
ated with cell differentiation and skeletal embryogenesis,
including those in the homeobox superfamily, were identiﬁed,
supporting a developmental component to these conditions.
There are several possible explanations for our ﬁndings: ﬁrst,
given that we have also observed inverse associations between
CDKN2A methylation and offspring adiposity,(16) the relation-
ships with bone might have been mediated through fat or lean
mass. However, when we adjusted for DXA whole-body fat or
lean mass in the multivariate models, the CDKN2A-bone
relationships remained robust. Second, it is possible that
CDKN2A methylation and childhood bone mass are both
inﬂuenced by a common factor during intrauterine life. In this
situation, one might expect that the CDKN2A-bone relationships
would be attenuated through adjustment for birthweight, but
we found that statistically signiﬁcant relationships remained
(Supplemental Table S4), althoughweremarkedly attenuated by
inclusion of current weight in the model. This latter observation
is difﬁcult to interpret owing to the high correlation between
body weight and bone indices, but the persisting associations
between perinatal CDKN2A methylation and bone indices after
adjustment for childhood height suggests that they are not
mediated by skeletal size alone. Finally, it is possible that
CDKN2Amethylation in umbilical cord tissue does have a causal
relationship with bone development, particularly given the
common mesenchymal origin of elements of both tissues, such
that the alterations to methylation detected in umbilical cord
tissue are consistent with changes in bone tissue or that the
umbilical cord methylation marks inﬂuence other processes,
which in turn inﬂuence bone development. It seems intuitively
reasonable that a resetting of gene expression, via epigenetic
marking, might have a long-term inﬂuence on skeletal growth.
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Our epidemiological ﬁndings are supported by our in vitro
investigations, in which we demonstrated the functional
importance of these CpG dinucleotides for ANRIL expression
and that DNA methylation affects protein binding in the region,
results that indicate the functional relevance of the methylation
signals, including potential roles for speciﬁc transcription
factors. Importantly, although elucidation of the causal (or
not) nature of the associations is essential for mechanistic
understanding and identiﬁcation of potential therapeutic
targets, it is less important in terms of risk stratiﬁcation and
identiﬁcation of those individuals potentially at increased risk of
low bone density in old age.
We used a prospective cohort with detailed characteriza-
tion of mothers and children, using the gold standard DXA
technique to assess bone mass. There are, however, several
limitations to our study. First, although we previously
excluded the presence of a SNP at the CpG sites of interest
by sequencing,(17) it is not possible to exclude a genetic
trans-effect of distant SNPs that could inﬂuence both DNA
methylation of a particular sequence and child’s phenotype.
Second, we analyzed methylation in cells from whole
umbilical cord; although it is possible that the differential
methylation we observed arose from variation in the
proportions of different component cells (for example,
ﬁbroblasts, epithelial cells) in individual samples, our results
were consistent across both our Discovery and Replication
set. Also, our studies show similar methylation in different
umbilical cord cell types (unpublished). Furthermore, any
unaccounted cell-heterogeneity that is being observed as
epigenetic change may represent proportional differences
that are related to the phenotypic outcomes.(48) Third, we
were not able to assess CDKN2A DNA methylation in bone
itself because of the difﬁculties in obtaining such samples
from children and have therefore used DNA methylation in
the cord as a proxy. There are a growing number of studies
that have found that the methylation status of CpGs in
peripheral tissues such as blood correlates with that of
internal tissues.(49,50) In addition, both bone and cord tissue
are derived from the mesoderm and share mesenchymal cell
origins; mesenchymal stem cells differentiate into osteo-
blasts, playing a role in bone formation both in the
embryo(51) and in the adult, in fracture and repair mecha-
nisms.(52) Fourth, we could not examine whether the changes
in methylation were associated with differences in the
expression of transcripts from this locus, however; although
methylation changes may be tissue-independent, altered
gene expression patterns would most likely be cell type–
dependent and reliant upon cell-speciﬁc transcription factor
expression whose function is then modulated by altered
access to the underlying DNA as a result of altered
methylation patterns. Fifth, measurement of bone mineral
in children is hampered by their low absolute BMC. However,
we used speciﬁc pediatric software, and studies of DXA
indices compared with ashed mineral content in piglets have
conﬁrmed the accuracy of the technique.(53) Sixth, the study
cohort was a subset of the SWS, but mothers whose children
underwent DXA scanning and those whose children did not
were broadly similar: The former were on average slightly
older and smoked slightly less. There is no reason to suppose,
however, that relationships between CDKN2A promoter
methylation in umbilical cord and childhood bone mineral
accrual would differ between these two groups. Seventh, it
should be noted that our Study and Replication cohorts were
both located in Southampton, UK, forming part of the
Southampton Women’s Survey. Ideally, these results would
go on to be replicated in a geographically separate and
possibly ethnically diverse cohort. Finally, the use of DXA
does not allow measurement of true volumetric bone
density, thus making it difﬁcult to be certain about
differential determinants of skeletal size and volumetric
density.
In conclusion, we have demonstrated that increasing
methylation at CpG sites within CDKN2A in umbilical cord is
associated with decreased bone size, mineral content, and
mineral density in childhood, that these CpG sites are
functionally important for local gene expression, and that
DNA methylation alters transcription factor binding within the
region. These ﬁndings yield mechanistic insights into the early
determinants of skeletal growth and may identify novel
biomarkers for future adverse bone development.
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